Allarity Therapeutics Q1 2025: Minimal Revenue, Assets $17M
Ticker: ALLR · Form: 10-Q · Filed: May 9, 2025 · CIK: 1860657
Sentiment: neutral
Topics: financials, 10-Q, pharmaceuticals
TL;DR
Allarity Therapeutics Q1 2025: Assets $17M, Liabilities $7.3M, Revenue negligible.
AI Summary
Allarity Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported minimal revenue for the first quarter of 2025, with $0.0001 in both revenue and cost of revenue. Total assets were $17,021,970, and total liabilities were $7,302,797 as of March 31, 2025.
Why It Matters
This filing provides a snapshot of Allarity Therapeutics' financial health at the start of 2025, indicating a company with significant assets but very low revenue generation.
Risk Assessment
Risk Level: medium — The company has substantial liabilities relative to its minimal revenue, suggesting potential financial instability.
Key Numbers
- $17.0M — Total Assets (As of March 31, 2025)
- $7.3M — Total Liabilities (As of March 31, 2025)
- $0.0001 — Q1 2025 Revenue (Indicates minimal operational revenue)
- $250,000,000 — Authorized Shares (Reflects potential for future equity financing)
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Filer of the 10-Q
- 2025-03-31 (date) — End of reporting period
- $17,021,970 (dollar_amount) — Total assets as of March 31, 2025
- $7,302,797 (dollar_amount) — Total liabilities as of March 31, 2025
- $0.0001 (dollar_amount) — Revenue for Q1 2025
FAQ
What is the primary business of Allarity Therapeutics, Inc.?
Allarity Therapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
What was the reported revenue for the first quarter of 2025?
The reported revenue for the first quarter of 2025 was $0.0001.
What were the total assets of the company as of March 31, 2025?
The total assets of Allarity Therapeutics, Inc. as of March 31, 2025, were $17,021,970.
What were the total liabilities of the company as of March 31, 2025?
The total liabilities of Allarity Therapeutics, Inc. as of March 31, 2025, were $7,302,797.
What is the company's fiscal year end?
Allarity Therapeutics, Inc.'s fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 9, 2025 regarding Allarity Therapeutics, Inc. (ALLR).